Unimartpharma Private Limited
Pharmaceutical trading company incorporated in 2020 with registered office in Maharashtra.
2020 | Mumbai, Maharashtra (India) | Active
Unimartpharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 275.07%
- Profit Growth 468.79%
- Ebitda -1023.30%
- Net Worth 89.89%
- Total Assets 38.05%
About Unimartpharma
Unimartpharma Private Limited (UPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 May 2020 (Four years and nine months 10 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ajay Sahu and Pradeep Singh serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909MH2020PTC339828
- Company No.
339828
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 May 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Pharma
Who are the key members and board of directors at Unimartpharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajay Sahu  | Director | 19-May-2020 | Current |
| Pradeep Singh | Director | 19-May-2020 | Current |
Financial Performance of Unimartpharma.
Unimartpharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 275.07% increase. The company also saw a substantial improvement in profitability, with a 468.79% increase in profit. The company's net worth Soared by an impressive increase of 89.89%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unimartpharma?
In 2021, Unimartpharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Unimartpharma?
Unimartpharma has a workforce of 0 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unimartpharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unimartpharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
